A focused 2026 clinical landscape deep dive into ChiCTR2600127775, evaluating BCG Live(Organon & Co.) in Urothelial Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07648030, evaluating Rusfertide acetate in Polycythemia Vera: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Lexicon Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07695740, evaluating YKST02 in Multiple Myeloma Sequencing: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07698535, evaluating Docetaxel in Metastatic Castration-Resistant Prostate Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into ChiCTR2600128153, evaluating Trastuzumab in HER2-Low Breast Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Fractyl Health 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Rhythm Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Corcept Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Metsera 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Altimmune 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Structure Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.